Skip to main content

Functional Constipation (FC)

2
Pipeline Programs
3
Companies
2
Clinical Trials
1 recruiting
1
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
1
1
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Peptide
2100%
+ 1 programs with unclassified modality

On Market (1)

Approved therapies currently available

AbbVie
LINZESSApproved
linaclotide
AbbVie
Guanylate Cyclase-C Agonist [EPC]oral2012
1.8B Part D

Competitive Landscape

3 companies ranked by most advanced pipeline stage

AbbVie
AbbVieNORTH CHICAGO, IL
1 program
1
1
LinaclotidePhase 3Peptide1 trial
Active Trials
NCT05652205Completed123Est. Sep 2025
UNION therapeutics
UNION therapeuticsDenmark - Hellerup
1 program
Intervention with probiotic bacteriaN/A1 trial
Active Trials
NCT06802042Recruiting40Est. Dec 2026
Ironwood Pharmaceuticals
1 program
LinaclotidePHASE_3Peptide

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
AbbVieLinaclotide
UNION therapeuticsIntervention with probiotic bacteria

Clinical Trials (2)

Total enrollment: 163 patients across 2 trials

A Study to Assess Adverse Events and Change in Symptoms With Linaclotide Versus Placebo in Pediatric Subjects, Ages 2 to 5 Years, With Functional Constipation

Start: Dec 2022Est. completion: Sep 2025123 patients
Phase 3Completed
NCT06802042UNION therapeuticsIntervention with probiotic bacteria

Effect of Lactobacillus DSM17938+ on Functional Constipation and Intestinal Flora in Pregnant Women

Start: Jan 2025Est. completion: Dec 202640 patients
N/ARecruiting

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 163 patients
Peptide is the dominant modality (100% of programs)
3 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.